CPA
CORT icon

Capital Performance Advisors’s Corcept Therapeutics CORT Stock Holding History

Capital Performance Advisors’s Portfolio CORT Stock Details CORT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q4 		– Sell
-538
Closed -$24.9K – 714
2024
Q3 		$24.9K Buy
+538
New +$19.1K 0.01% 535

Other funds holding CORT

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
ISL
Ingalls & Snyder LLC New York $3.66B AUM 57.76% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return
PA
Parallel Advisors San Francisco, California $6.56B AUM 32.24% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $552B AUM 44.19% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Arrowstreet Capital
Arrowstreet Capital Boston, Massachusetts $225B AUM 49.49% 1-Year Est. Return
Jacobs Levy Equity Management
Jacobs Levy Equity Management Florham Park, New Jersey $27.8B AUM 46.46% 1-Year Est. Return

Capital Performance Advisors's CORT Position: Q4 2024 in Review

Capital Performance Advisors sold out of Corcept Therapeutics (CORT) in Q4 2024, closing a stake of 538 shares — an estimated $24.9K sold.

Capital Performance Advisors first reported a position in CORT in Q3 2024 and held it in 1 quarter. The position peaked at $24.9K in Q3 2024. 367 funds tracked by Wall St. Rank hold CORT as of Q4 2024.

  • Capital Performance Advisors reported no remaining Corcept Therapeutics position as of Q4 2024 after selling out during the quarter.
  • Capital Performance Advisors sold 538 Corcept Therapeutics shares in Q4 2024, an estimated $24.9K.
  • Capital Performance Advisors first reported a position in Corcept Therapeutics in Q3 2024 and held it in 1 quarter.
  • Capital Performance Advisors's Corcept Therapeutics position peaked at $24.9K in Q3 2024.
  • 367 funds tracked by Wall St. Rank held Corcept Therapeutics as of Q4 2024.

Based on Capital Performance Advisors's 13F filing for Q4 2024, filed 31 Jan 2025.